8.50
+0.05(+0.59%)
Currency In USD
| Previous Close | 8.45 |
| Open | 8.31 |
| Day High | 8.62 |
| Day Low | 8.31 |
| 52-Week High | 11.78 |
| 52-Week Low | 3.76 |
| Volume | 1.27M |
| Average Volume | 1.09M |
| Market Cap | 1.34B |
| PE | -6.59 |
| EPS | -1.29 |
| Moving Average 50 Days | 9.99 |
| Moving Average 200 Days | 8.17 |
| Change | 0.05 |
If you invested $1000 in Ocular Therapeutix, Inc. (OCUL) 10 years ago, it would be worth $382.02 as of December 21, 2024 at a share price of $8.5. Whereas If you bought $1000 worth of Ocular Therapeutix, Inc. (OCUL) shares 5 years ago, it would be worth $1,990.63 as of December 21, 2024 at a share price of $8.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 10, 2024 12:30 PM GMT
BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovat
Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1
GlobeNewswire Inc.
Dec 02, 2024 12:30 PM GMT
SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4 2025 Active clinical trial sites enrolling patients directly into second registrational trial, SOL-R, while additional sites continue to b
Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences
GlobeNewswire Inc.
Nov 26, 2024 12:30 PM GMT
BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innova